This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

28/100

✓ Peer-reviewed alzhub usefulness score 28 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Anti-amyloid immunotherapy agents represent a novel and clinically significant class of humanized monoclonal antibodies designed to selectively bind and clear pathological amyloid-beta (Aβ) aggregates from the brain, thereby slowing the progression of early Alzheimer’s disease (AD). Alzheimer’s disease is the leading cause of dementia globally, affecting over 55 million individuals worldwide and nearly 600,000 Canadians, with no previously approved disease-modifying therapy available prior to this class (World Health Organization, 2023; Alzheimer Society of Canada, 2022). This article provides a comprehensive review of anti-amyloid immunotherapy as a therapeutic class, covering its mechanism of action, clinical indications, dosage forms, physicochemical properties, container closure systems, safety profile, and emerging technologies in manufacturing and drug delivery. The article further outlines the preparation of a New Drug Submission (NDS) to Health Canada using the Common Technical Document (CTD) format, with emphasis on class-specific considerations including amyloid biomarker confirmation, amyloid-related imaging abnormality (ARIA) risk management, and biologics-specific quality requirements. Evidence-based recommendations for regulatory professionals are provided.

Key findings

Anti-amyloid immunotherapy agents represent a novel and clinically significant class of humanized monoclonal antibodies designed to selectively bind and clear pathological amyloid-beta (Aβ) aggregates from the brain, thereby slowing the progression of early Alzheimer’s disease (AD).

Why it matters

This review describes anti-amyloid immunotherapy agents as humanized monoclonal antibodies that bind and clear pathological amyloid-beta aggregates from the brain, thereby slowing progression of early Alzheimer's disease. It covers regulatory considerations including amyloid biomarker confirmation and ARIA risk management for a New Drug Submission to Health Canada.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Evidence strengthLow

How this study scored 28/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, so that was left out: it earned 27 of the 96 points we could judge it on, which is 28 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Zenodo (CERN European Organization for Nuclear Research))
Journal's citation record	— / 4	No journal record from OpenAlex — left out of this score
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 2 year(s) since 2026
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	0 / 4	Last-listed author Peivand Pirouzi: h-index 0 (OpenAlex, whole career)
Institution's track record	1 / 3	Northeastern University: institution h-index 706 (OpenAlex)
Multi-centre collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	1 / 2	Not in PubMed, but has a DOI
Free to read	2 / 2	Free to read
Points	27 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 27 of the 96 points we could judge it on is 28 out of 100.
Total	28 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Patel, P., Rana, A., Pansuria, M., Patel, R., Patel, H., & Pirouzi, P. (2026). Perspectives and Insights on Anti-Amyloid Immunotherapy Agents: From Development to Submission of a New Drug Submission (NDS) in Canada. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.21339385

Vancouver

Patel P, Rana A, Pansuria M, Patel R, Patel H, Pirouzi P. Perspectives and Insights on Anti-Amyloid Immunotherapy Agents: From Development to Submission of a New Drug Submission (NDS) in Canada. Zenodo (CERN European Organization for Nuclear Research). 2026. doi:10.5281/zenodo.21339385.

BibTeX

@article{patel2026-08718bfc,
  author  = {Patel, Princy and Rana, Aarti and Pansuria, Mayur and Patel, Rutvik and Patel, Hemangini and Pirouzi, Peivand},
  title   = {{Perspectives and Insights on Anti-Amyloid Immunotherapy Agents: From Development to Submission of a New Drug Submission (NDS) in Canada}},
  journal = {Zenodo (CERN European Organization for Nuclear Research)},
  year    = {2026},
  doi     = {10.5281/zenodo.21339385},
  url     = {https://doi.org/10.5281/zenodo.21339385}
}

Related studies in Treatments

Also in Treatments

166 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →